2026 LCK Cup Finals in Hong Kong presented by CGA to Stage Historic Showdown in the City

Kai Tak Sports Park Set to Become the Global Esports Focal Point

HONG KONG, Jan. 27, 2026 /PRNewswire/ — The League of Legends Champions Korea (LCK), one of the world’s premier esports leagues, is set to reach a historic milestone. The 2026 LCK Cup Finals in Hong Kong SAR presented by CGA will be staged outside Korea for the first time, marking the Finals’ first overseas edition. The event will take place from 28 February to 1 March 2026 at Kai Tak Arena, Kai Tak Sports Park, and has been recognized as a “M” Mark major sports event in Hong Kong, it marks the arrival of a world‑class esports spectacle in Hong Kong.

Jointly presented by Cyber Games Arena (CGA) and the LCK organizer, the event represents a milestone in bringing top-tier League of Legends competition to fans outside Korea. Held over two consecutive days, the Finals are expected to attract more than 10,000 spectators per day, turning Kai Tak Sports Park into a major focal point for esports fans around the world.

LCK: Widely Recognised as the Highest-Level Professional League of Legends Competition

The LCK has long been regarded as one of the strongest and most competitive professional League of Legends leagues globally. It brings together the world’s top teams and legendary players and has been a dominant force on the international stage for many years. Teams from the LCK consistently occupy leading positions in the Global Power Rankings, including powerhouse organisations such as T1 and Gen.G, whose competitive standard is widely considered the benchmark of excellence.

Among its players is Faker, the first inductee into the Hall of Leagues, the first six‑time champion in League of Legends esports history, and the player who led his team to three consecutive World Championship titles. Other world‑class stars such as Gumayusi, ShowMaker, Bdd, and Chovy all compete in the LCK. The top three teams from LCK Cup 2026 will advance to Hong Kong to contest the Finals, delivering a series of dream matchups for local and international fans.

The 2026 LCK Cup Finals in Hong Kong presented by CGA will bring the most decisive stage of the tournament to Hong Kong:

• 28 February (Saturday): Loser Finals
• 1 March (Sunday): Finals
• Match Start Time: 16:00
• Venue: Kai Tak Arena

Each match day will feature one high‑intensity best‑of‑five (Bo5) series, will directly determine which teams qualify for the next tier of international competition. The top two teams emerging from the Hong Kong Finals will earn the right to represent the LCK at the world‑class international tournament First Stand Tournament (League of Legends Global Vanguard Tournament). As such, the Hong Kong stop is not only a championship showdown, but also a pivotal gateway to the global stage.

World-Class Venue for World-Class Competition

The tournament will be hosted at the recently completed Kai Tak Sports Park, providing spectators with the opportunity to witness the world’s top League of Legends teams compete at the highest level in a world‑class indoor arena. The intense on‑site atmosphere and live viewing experience will offer fans a level of immersion and excitement that simply cannot be replicated through online broadcasts.

Festival Zone with Free Admission. An Esports Carnival for the Entire Community

In addition to the main event, the Organizing Committee will establish a Festival Zone within the shopping mall and event venue during the competition period. The Festival Zone will be open to the public free of charge, inviting residents and visitors across Hong Kong to experience the dynamic atmosphere of the 2026 LCK Cup Finals in Hong Kong presented by CGA.

The LCK Festival Zone serves as the official fan engagement initiative held annually alongside the LCK Finals and is recognized as one of the most anticipated experiential components of the tournament. The 2026 edition will feature a comprehensive array of interactive activations, including team presentation booths, official and limited-edition merchandise outlets, designated photo and check-in areas, a Cheer Wall for fan messages, cosplayer appearances, and sponsor-led brand experience zones. Through this diverse and immersive offering, the Festival Zone aims to enhance audience engagement, strengthen community connection, and further reinforce Hong Kong’s position as a premier destination for international esports events.

LCK 2026 Festival Zone – Pop-Up Store

• Dates: 14 February – 1 March 2026
• Location: MCP CENTRAL, Metro City Plaza Phase 2 – L2 Atrium Footbridge
• Pop-Up Store Highlights: 
  • Official and limited-edition merchandise sales
  • Themed photo and check‑in areas

LCK 2026 Festival Zone (Kai Tak Arena)

• Dates: 28 February and 1 March 2026
• Location: Kai Tak Arena
• Festival Zone Highlights: 
  • Team booths
  • Official and limited-edition merchandise sales
  • Themed photo and check‑in areas
  • Cheer Wall for fan messages
  • Cosplayer meet‑ups and activities
  • Interactive experience zones hosted by sponsoring brands

The Festival Zone will be open before and during the competition days, featuring a wide variety of interactive experiences. Even those who are not regular esports viewers will be able to participate through these diverse activities and share in the excitement of a world‑class esports event together with esports fans and members of the public from all walks of life.

Tickets to Go on Sale – Global Esports Community on High Alert

Following the official announcement of the event, a significant surge in ticket demand is expected. The ticketing information is as follows:

Ticketing Information:

• Ticketing Platform: HK Ticketing (https://hkt.hkticketing.com/hant/#/news/detail/0/25)
• On-Sale Dates: 
  • PAYKOOL Priority Sale: 29 January, 10:00 a.m. – 8:00 p.m.
  • Public Sale via HK Ticketing: From 30 January, starting 10:00 a.m.
• Ticket Prices: HK$1,688 / HK$1,388 / HK$1,188 / HK$888 / HK$688 / HK$488
• Travel package platform : Trip.com
• Official Merchandises pre-order：https://lckmerch.cga.gg/

About the Event

The 2026 LCK Cup Finals in Hong Kong presented by CGA is proud to be recognised as an “M”Mark event, supporting the enhancement of Hong Kong’s status as a centre for major international sports events. The “M”Mark awarded by the Major Sports Events Committee signifies major sports events that are exciting, world‑class and highly engaging.

• Event Name: 2026 LCK Cup Finals in Hong Kong presented by CGA
• Dates: 28 February – 1 March 2026 (Saturday and Sunday)
• Time: Matches start at 16:00
• Venue: Kai Tak Arena

Tournament Format:

• 28 February (Saturday): Loser Finals
• 1 March (Sunday): Finals

Ticketing Information:

• Ticketing Platform: HK Ticketing (https://hkt.hkticketing.com/hant/#/news/detail/0/25)
• On-Sale Dates: 
  • PAYKOOL Priority Sale: 29 January, 10:00 a.m. – 8:00 p.m. 
    (https://premier.hkticketing.com)
  • Public Sale via HK Ticketing: From 30 January, starting 10:00 a.m.
    (https://premier.hkticketing.com)
• Ticket Prices: HK$1,688 / HK$1,388 / HK$1,188 / HK$888 / HK$688 / HK$488
• Travel package platform : Trip.com
• Official Merchandises pre-order：https://lckmerch.cga.gg/ 

Other information for downloading: https://tinyurl.com/LCK2026HK 

ABU DHABI, UAE, Jan. 27, 2026 /PRNewswire/ — Blue Planet Environmental Solutions, a Singapore headquartered sustainability and circular economy company, has achieved a major milestone in its Middle East growth strategy with the signing of a representative agreement and strategic Memorandum of Understanding with Majees Technical Services LLC, Oman. The collaboration coincided with Blue Planet’s active participation at the World Future Energy Summit 2026, held from 13 to 15 January 2026 at ADNEC, Abu Dhabi.

The agreement formally marks Blue Planet’s entry into Oman and establishes a long term partnership to jointly pursue opportunities across integrated waste management, landfill mining and remediation, tank cleaning, resource recovery, biogas solutions, and waste to value infrastructure. While the initial focus will remain on Oman, the partnership is structured to enable future expansion across other GCC markets. The collaboration brings together Blue Planet’s technology driven, IP based environmental solutions with Majees’ strong regional execution capabilities, institutional relationships, and deep local presence.

This partnership represents a significant step in Blue Planet’s strategy to deliver execution ready, locally anchored sustainability solutions aligned with national priorities across the region, including landfill diversion, circular economy adoption, and climate resilience goals.

Blue Planet’s participation at the World Future Energy Summit 2026 further reinforced its growing role in shaping regional and global conversations on circular economy implementation, climate aligned infrastructure, and large scale legacy waste remediation. Recognised as one of the world’s leading sustainability platforms, the Summit convenes policymakers, government authorities, infrastructure developers, technology providers, and investors to accelerate practical solutions for the energy transition and environmental sustainability.

As part of the Circular Economy Conference at the Summit, Blue Planet led a dedicated industry workshop on landfill mining and landfill remediation, hosted by Tadweer and attended by leading sector experts. The session highlighted structured remediation approaches, emissions reduction pathways, resource recovery potential, and sustainable land reuse, supported by global case studies and implementation frameworks.

During the Summit, Blue Planet engaged extensively with government bodies, municipal authorities, infrastructure developers, and waste management stakeholders, exploring how circular economy principles can be translated into scalable and bankable projects that deliver measurable environmental and economic impact.

Commenting on the milestone, Prashant Singh, Co Founder and Chief Executive Officer of Blue Planet Environmental Solutions, said:

“The signing of this MoU with Majees Technical Services marks an important milestone in Blue Planet’s GCC journey. Strong regional partnerships are essential to delivering execution ready and locally relevant environmental solutions at scale. The World Future Energy Summit provides a powerful platform to bring policymakers, industry leaders, and practitioners together around shared sustainability priorities and to move from ambition to implementation. Through this collaboration, we are well positioned to contribute meaningfully to the region’s circular economy and climate objectives with solutions that create long term value.”

Blue Planet continues to expand its portfolio of technology enabled environmental services, with a strong focus on landfill reclamation, waste valorisation, recycling, and bio energy solutions. Through strategic partnerships and participation in leading global sustainability forums, the company remains committed to advancing practical pathways toward resource efficiency and Zero Waste to Landfill outcomes across the GCC and beyond.

About Blue Planet Environmental Solutions

Founded in 2017, Blue Planet Environmental Solutions is a Singapore-headquartered sustainability company pioneering regional impact through technology-driven, IP-based, end-to-end waste management and circular economy solutions. Operating across Southeast Asia, India, the UK, New Zealand, and the Middle East, Blue Planet’s capabilities span landfill mining and remediation, hazardous and e-waste recycling, biogas and bio-energy solutions, and resource recovery. The company’s mission is to create scalable circular ecosystems that extract higher value from waste, reduce environmental footprints, and enable a resource-efficient economy, advancing its vision of Zero Waste to Landfill.

www.blueplanet.asia

About Majees Technical Services LLC

Majees is a leading Oman based EPC Company offering turnkey solutions across oil and gas, energy, fire, security, and telecom, as well as flare systems manufacturing.

www.majeestech.com 

Serving Singapore and beyond, Acker Wine Merchant provides collectors access to exclusive releases, private tastings, and unparalleled service through a dedicated international platform.

SINGAPORE, Jan. 27, 2026 /PRNewswire/ — Acker, the world’s largest fine wine auction house and America’s oldest wine merchant, has strengthened its international retail presence with dedicated sale hubs across Hong Kong, London, Japan, South Korean, Mainland China and now Singapore.

The company proudly unveils Acker Wine Merchant, bringing collectors in Singapore and beyond high-touch access to the world’s finest wines, supported by more than US$20 million of carefully curated stock. The platform offers tailored guidance to help collectors build and refine their cellars with confidence, while providing a single destination for exclusive releases, private tastings, and personalized service.

“We are launching a truly global service built on our legacy of excellence and deeply personal approach to client relationships,” said Irvin Goldman, Acker’s Global CEO and Co-owner.  “By uniting our expertise in London, Hong Kong and the US, we are uniquely positioned to serve the next generation of collectors across the world’s most dynamic markets.”

A Global Service for the Discerning Collector

Acker Wine Merchant offers a complete suite of services for private clients and retail collectors, entirely separate from Acker’s auction activities. With this launch, Acker reinforces its identity as the definitive leader in fine wine, committed to quality, authenticity and unparalleled client service on a global scale.

Clients will benefit from dedicated Wine Merchant Specialists providing a fully personalised, retail-only experience with curated selections of rare vintages and regional specialties. This is complemented by tailored advisory services surrounding acquisition, collection building and investment, and supported by a continued focus on sustainability and innovation through partnerships withleading producers.

Positioned as a true global wine merchant, the division will leverage a US$20 million fine wine inventory, enhanced storage capabilities for long-term investment and retail consignments, and significant capital availability for immediate buyouts. The client experience will be supported through a dedicated international website, a revamped e-commerce platform, and a calendar of exclusive events including tastings, masterclasses, and private dinners in London, Europe and Asia.

A New Era for Fine Wine Enthusiasts 

Drawing on Acker’s long-standing reputation for sourcing some of the rarest and most sought-after bottles, Acker Wine Merchant sets a new benchmark for fine wine retail and private client services in the region. The exceptional selection spans legendary Burgundy estates and cult producers, offering collectors access to wines celebrated for their rarity, provenance and investment-grade stature.

• Portfolio highlights include some of Burgundy’s most tightly held and historically significant estates, such as Domaine de la Romanée-Conti, Domaine Leroy, Coche-Dury, Domaine René Engel, Georges Roumier, and Jacky Truchot.

With its Singapore debut, Acker Wine Merchant offers discerning collectors a gateway to the world’s most prestigious labels, bolstered impeccable sourcing and centuries of expertise.

For full selection and more information: https://hk.ackerwines.com/wine-merchant/

About Acker Wines

Founded in 1820, Acker is America’s oldest wine merchant and the leading fine and rare wine auction house globally. Now in its third century, the company serves collectors worldwide through its full suite of fine wine services, including retail sourcing, auctions, cellar management and appraisals, investment advisement, bespoke events and tastings, wine excursions, and a world-class wine club. With a global platform spanning the United States, Europe, and Asia, Acker brings these capabilities together as The World’s Destination for Fine & Rare Wine™.

 

The 2026 edition of Eco Deals offers accommodation partners enhanced visibility while continuing to support the protection of wildlife and conservation of critical habitats in Asia

SINGAPORE, Jan. 27, 2026 /PRNewswire/ — Digital travel platform Agoda and the World Wide Fund for Nature (WWF) launch the fifth edition of Eco Deals, marking five years of impactful partnership and conservation achievements across Asia. The 2026 program will continue its highest funding commitment to-date of US$1.5 million to support conservation efforts in 10 markets across Asia. This year’s launch also marks the signing of a new five-year Memorandum of Understanding (MoU), strengthening the ongoing partnership between Agoda and WWF to advance conservation efforts, raise traveler awareness, and drive industry engagement for sustainable tourism throughout Asia.

Launching on 19 January, the 2026 Eco Deals program will begin with a month-long campaign offering travelers discounts of up to 20% at participating properties to mark the program’s fifth anniversary. The program will then continue with a year-round offering, providing savings of up to 15% for travelers until 18 December. Throughout the campaign, travelers can easily identify participating accommodations through dedicated program pages and on‑site identification features across Agoda’s platforms.  As in previous editions, Agoda will donate US$1 towards WWF`s conservation efforts for every completed program booking made at a participating hotel.

Eco Deals enables accommodation partners to support conservation efforts across Asian destinations, helping protect the natural environments and biodiversity that are essential to the region. In 2025, the program continued to scale across the region, growing to nearly 10,000 participating properties. Since it was first launched in 2022, Eco Deals has raised US$2.89 million for conservation projects, supporting efforts such as protecting the Malayan tiger in Malaysia, safeguarding Asian elephants in Thailand, and conserving whale sharks in the Philippines. These efforts contribute to broader regional progress towards the Kunming-Montreal Global Biodiversity Framework ’30×30′ goal, which aims to bring 30% of the world’s land and oceans under effective protection by 2030.

Participating partners will receive the Eco Deals badge, signaling their support to the protection of wildlife and nature across Asia. Partners will also benefit from marketing support across Agoda platforms, including targeted marketing placements such as banner promotions, customer communications, social media features and in-app discovery. Eco Deals properties will also be featured on dedicated program pages across Agoda’s desktop and mobile platforms, helping travelers discover and support accommodations whose bookings contribute to conservation efforts. Upon its conclusion, participating properties will receive a certificate recognizing their involvement in the program.

“Eco Deals reflects five years of collaboration with WWF to support conservation efforts to protect Asia’s most remarkable destinations, alongside a growing network of accommodation partners,” said Andrew Smith, Senior Vice President, Supply, Agoda. “The signing of a new five-year MoU with WWF is a testament to our shared vision and action for long-term conservation and industry collaboration. In the past year alone, the program has seen participating properties grow by more than 45%, with strong momentum in markets like Indonesia, the Philippines and Malaysia. But what’s most rewarding is seeing how Eco Deals has become a platform for hotels to differentiate themselves, connect with sustainability‑minded travelers and contribute to meaningful conservation work across Asia.”

“Nature is a source of wonder and a vital lifeline for communities and wildlife,” said Hsieh Fu Hua, Chairman, WWF-Singapore. “Eco Deals shows how the tourism industry can actively contribute to nature-positive outcomes while creating value for travelers and destinations alike. By working across markets and a broad network of stakeholders, this partnership helps link local conservation priorities with regional coordination to protect nature today and for future generations.”

With a global network of accommodations and travel offerings, Agoda remains committed to working with partners to support responsible travel and conservation initiatives across the region. Together with WWF, Agoda invites hotel partners to take part in this year’s Eco Deals program and contribute towards conservation initiatives across Asia. For more information, visit www.agoda.com/ecodeals.

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for the treatment of chronic hepatitis D virus infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of the large envelope protein of hepatitis B virus (HBV) and hepatitis D virus (HDV), thereby blocking viral entry into hepatocytes. As a groundbreaking achievement in viral hepatitis therapeutics, Libevitug is a first-in-class antibody therapeutic for viral hepatitis and the first approved treatment for HDV in China, addressing a major clinical gap in this field. The drug previously received “Breakthrough Therapy Designation” from both the Center for Drug Evaluation (CDE) of the China NMPA and the U.S. Food and Drug Administration (FDA).

Guidelines from the World Health Organization (WHO) and the European Association for the Study of the Liver (EASL) consistently identify HDV–HBV co-infection as the most severe form of chronic viral hepatitis due to rapid progression towards liver cirrhosis, hepatocellular carcinoma and liver-related death ^{[1] [2]}. HDV is a satellite virus that depends on HBV’s envelope proteins to complete its life cycle and therefore infects only individuals who are co-infected with HBV. Chronic HDV–HBV co-infection leads to a higher risk of cirrhosis and liver cancer compared to HBV mono-infection, accounting for approximately one in six cases of cirrhosis and one in five cases of liver cancer among people with HBV infection globally ^[3].

According to WHO, HDV affects nearly 5% (an estimated 12 million) of people who have a chronic infection with HBV. Given the severe consequences of HDV infection, WHO’s 2024 Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection recommend that serological testing for anti-HDV antibodies may be performed for all individuals who are HBsAg positive, as the preferred approach to scale up access to HDV diagnosis and linkage to care. In China, with over 75 million patients living with chronic hepatitis B, limited HDV therapies, compounded by inadequate clinical awareness and low testing rates, have left patients with no treatment options, underscoring a pressing unmet medical need.

Clinical development of Libevitug began in 2018. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter, randomized, controlled, open-label Phase IIb clinical trial demonstrated that Libevitug was significantly superior to the control group across primary and secondary efficacy endpoints including combined response rate, virological response, alanine aminotransferase (ALT) normalization, and improvement in liver stiffness. Libevitug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness.

“Libevitug demonstrates outstanding clinical efficacy and significantly improves liver stiffness, with particularly remarkable efficacy in patients with HBV/HDV-related cirrhosis,” stated Professor Niu Junqi, principal investigator of the Libevitug (HH003-204) trial from the First Hospital of Jilin University. “This drug aligns with the core objectives of China’s Action Plan for the Prevention and Control of Viral Hepatitis (2025–2030), which aims to improve diagnosis and treatment rates for viral hepatitis and reduce the incidence of liver cancer and mortality. We anticipate that Libevitug will help effectively lower the risk of disease progression to advanced severe diseases such as liver cancer, drive the standardization of HDV diagnosis and treatment in China, advance the goal of eliminating viral hepatitis as a public health problem by 2030, and contribute a scientifically robust and accessible solution from China to global hepatitis control efforts.”

The development of Libevitug stems from a scientific breakthrough over a decade in the making. In 2012, a team at the National Institute of Biological Sciences, Beijing (NIBS) led by Dr. Li Wenhui, scientific founder of Huahui Health, identified the sodium taurocholate cotransporting polypeptide (NTCP) as the critical receptor for HBV and HDV infections—a world-first discovery solving a decades-long scientific mystery. This landmark achievement earned Dr. Li prestigious accolades, including the Baruch S. Blumberg Prize, the Future Science Prize, and the Distinguished Award in Hepatitis B Research, and opened a door for new drug development. In 2015, the lead molecule of Libevitug was developed through a collaboration between Dr. Sui Jianhua, co-founder of Huahui Health and an antibody engineering expert, and Dr. Li’s team. “The global burden of viral hepatitis is immense,” stated Dr. Sui. “We are pleased that Libevitug is the first monoclonal antibody approved in this field, effectively treating the most severe and progressive form of chronic viral hepatitis—HDV co-infection with HBV.” Dr. Li added, “We are grateful for the invaluable support from all our partners and collaborators. The teams at Huahui Health and NIBS have worked together to complete the full-cycle of biomedical innovation from ‘uncovering fundamental mechanism’ to ‘developing effective drugs’, positioning us at the leading edge of this field and demonstrating our capability and commitment to tackling critical challenges in human health.”

Dr. Chen Bin, Chief Executive Officer of Huahui Health, stated, “The successful approval of Libevitug fulfills our commitment to building a world-class translational and clinical development platform dedicated to delivering innovative therapies for patients worldwide. We have established an integrated R&D system covering the entire drug development process, with a pipeline expanding from HDV and HBV to oncology and other liver diseases, comprising eight core asset candidates. Going forward, we remain steadfastly committed to our vision of ‘Original in China, Benefiting the Globe’, leveraging science to safeguard global healthcare in infectious and liver diseases.”

References:

[1] World Health Organization. Hepatitis D Fact Sheet. https://www.who.int/news-room/fact-sheets/detail/hepatitis-d
[2] European Association for the Study of the Liver. J Hepatol. 2023 Aug; 79(2)433-460.
[3] WHO. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. 2024.

About Chronic HDV Infection

HDV is a satellite virus of HBV, relying on HBV’s envelope proteins to complete its life cycle. HDV infects hepatocytes by binding to NTCP, a receptor shared with HBV. HDV infection occurs only in individuals with concurrent HBV infection. Compared to HBV mono-infection, co-infection with HBV and HDV significantly increases—often doubling—the risk of developing liver cirrhosis, hepatocellular carcinoma (HCC), requiring liver transplantation, and liver-related mortality, making it the most severe known form of chronic viral hepatitis. According to the WHO, approximately 12 million people worldwide are infected with HDV, affecting nearly 5% of all chronic HBV carriers. WHO recommends screening and testing for hepatitis D in all hepatitis B surface antigen (HBsAg)-positive individuals. Until now, aside from Europe, no drugs for chronic HDV infection had been approved in China or the United States.

About Libevitug (HH-003)

Libevitug is a first-in-class, PreS1-targeting neutralizing monoclonal antibody against HBV/HDV, discovered and developed by Huahui Health. The antibody functions by specifically blocking the interaction between the viral PreS1 domain and the host NTCP receptor, preventing viral entry into hepatocytes and reinfection. The early-stage development of Libevitug received support from the National Major Science and Technology Project for Significant New Drugs Development under China’s 13th Five-Year Plan. Previously, it was granted Breakthrough Therapy Designation (BTD) for Hepatitis D by both China’s CDE, NMPA (2023) and the U.S. FDA (2024).

About Huahui Health

Founded in Beijing in 2015, Huahui Health is a biopharmaceutical company dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. Driven by a patient-centric philosophy and profound scientific expertise, Huahui Health operates under the core principles of Innovation, Integrity, Collaboration, and Mutual Benefit. Huahui Health has built integrated, world-class proprietary platforms that cover the entire new drug development process, ensuring sustained delivery of breakthrough therapies for patients worldwide.

For more information, please visit www.huahuihealth.com.

BEIJING, Jan. 27, 2026 /PRNewswire/ — Huahui Health announced that China’s National Medical Products Administration (NMPA) has granted conditional approval to its Libevitug injection for chronic hepatitis D virus (HDV) infection in adults with or without compensated cirrhosis. Libevitug is a human monoclonal antibody targeting the PreS1 domain of hepatitis B virus (HBV) and HDV envelope proteins, blocking viral entry into hepatocytes. As a groundbreaking advance in viral hepatitis care, it is China’s first approved HDV therapy and a first-in-class antibody for viral hepatitis, addressing a critical clinical gap.

According to the World Health Organization (WHO), HDV affects nearly 5% (an estimated 12 million) of people with chronic HBV infection. HDV–HBV co-infection is considered the most severe form of chronic viral hepatitis due to more rapid progression towards hepatocellular carcinoma and liver-related death. 

Libevitug was previously granted “Breakthrough Therapy Designation” by China’s NMPA and the U.S. FDA. Data from its pivotal registrational study (HH003-204) were presented as a Late-Breaker Abstract at the 2025 Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). This international, multicenter, randomized, controlled, open-label Phase IIb clinical trial demonstrated that Libevitug was significantly superior to the control group across primary and secondary efficacy endpoints including combined response, virological response, alanine aminotransferase (ALT) normalization rate, and improvement in liver stiffness. The drug also showed favorable tolerability and a satisfactory safety profile. At Week 48, the combined response rate reached 44.1%, along with an HDV RNA virological response rate of 60% and an ALT normalization rate of 70%, and a significant, sustained improvement in liver stiffness. Libevitug is poised to provide a novel and accessible treatment option for hepatitis D patients worldwide.

Huahui Health is dedicated to developing first-in-class and best-in-class therapies, with a strategic focus on viral hepatitis, liver diseases, and oncology. It has established an integrated R&D system covering the entire drug development process, enabling it to continuously deliver breakthrough therapies for patients across the globe.

About Huahui Health

Huahui Health is a biopharmaceutical company headquartered in Beijing, dedicated to innovating breakthrough therapies in virology, hepatology and oncology through its proprietary, world-class drug development platforms.

For more information, please visit www.huahuihealth.com.